Aniracetam

Pricing Availability Delivery Time Qty
Cat.No. 0867 - Aniracetam | C12H13NO3 | CAS No. 72432-10-1
Description: Desensitization inhibitor (AMPA > kainate)
Chemical Name: 1-(4-Methoxybenzoyl)-2-pyrrolidinone
Purity: ≥99% (HPLC)
Datasheet
Citations
Literature

Biological Activity

Nootropic, with modulatory actions through allosteric potentiation of AMPA specific receptors, reduction of glutamate receptor desensitization and potentiation of metabotropic glutamate receptor activity. Anxiolytic following systemic administration.

Compound Libraries

Aniracetam is also offered as part of the Tocriscreen Plus. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 219.24
Formula C12H13NO3
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 72432-10-1
PubChem ID 2196
InChI Key ZXNRTKGTQJPIJK-UHFFFAOYSA-N
Smiles COC1=CC=C(C=C1)C(=O)N1CCCC1=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 21.92 100
ethanol 5.48 25

Preparing Stock Solutions

The following data is based on the product molecular weight 219.24. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 4.56 mL 22.81 mL 45.61 mL
5 mM 0.91 mL 4.56 mL 9.12 mL
10 mM 0.46 mL 2.28 mL 4.56 mL
50 mM 0.09 mL 0.46 mL 0.91 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Safety Datasheet

References

References are publications that support the products' biological activity.

Isaacson and Nicholl (1991) Aniracetam reduces glutamate receptor desensitisation and slows the decay of fast excitatory synaptic currents in the hippocampus. Proc.Natl.Acad.Sci.U.S.A. 88 10936 PMID: 1660156

Ito et al (1990) Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J.Physiol. 424 553 PMID: 1975272

Nakamura and Kurasawa (2001) Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur.J.Pharmacol. 420 33 PMID: 11412837


If you know of a relevant reference for Aniracetam, please let us know.

View Related Products by Target

View Related Products by Product Action

View all AMPA Receptor Inhibitors

Keywords: Desensitization inhibitors inhibits AMPA kainate Glutamate Receptors iGluR Ionotropic allosteric modulators potentiators AMPA Receptors

Citations for Aniracetam

Citations are publications that use Tocris products.

Currently there are no citations for Aniracetam. Do you know of a great paper that uses Aniracetam from Tocris? If so please let us know.

Commented out for usability testing

Reviews

TODO: Add Reviews

Literature in this Area

Pain

Pain Research Product Guide

A collection of over 250 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Addiction

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Alzheimer's

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Learning & Memory

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Pain

Pain Poster

Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.

Schizophrenia

Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.

Pathways for Aniracetam

Protocols

TODO: Add Protocols